•  
  •  
  •  
  •  

2026-07-24 11:20:52

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Mphasis Reports 17.5% YoY Revenue Growth in Q1 FY27; Secures $461 Million in New Deal Wins Driven by AI Demand
  • Fractal Analytics Reports 20% Revenue Growth and 92% Surge in Net Income for Q1 FY27
  • Route Mobile Ltd Financial Results Reveal Strong Operational Top-Line Expansion for Q1 FY27 as Revenue Reaches ₹1,151.51 Crore
  • CyberTech Systems and Software Limited Reports Q1 FY27 Net Profit Up 16% YoY to ₹9.48 Crore as Operational Revenue Reaches ₹68.45 Crore
  • ACME Solar operationalizes 3.62 GWh Battery Energy Storage System projects in Rajasthan

Keywords Selected:  StridesPharmaGlobal

Stock Report

  • Strides receives USFDA approval for Acetaminophen and Ibuprofen Tablets, 125 mg /250 mg, Expanding the Existing OTC Portfolio
  • Strides receives USFDA approval for Fluoxetine Tabs 60 mg
  • Strides receives USFDA approval for Sevelamer Carbonate Tablets, 800 mg
  • Strides receives USFDA approval for Fluoxetine Tabs 10 mg and 20 mg
  • Strides receives USFDA approval for Pregabalin Capsules
  • Strides receives USFDA approval for Generic Suprep® Bowel Prep Kit
  • Strides receives USFDA approval for Levetiracetam Oral Solution
  • Strides receives USFDA approval for Efavirenz, Emtricitabine & Tenofovir Disoproxil Fumurate tablets
  • Strides receives USFDA approval for Icosapent Ethyl Capsules
  • Strides receives USFDA approval for Icosapent Ethyl Capsules
  • Strides receives tentative USFDA approval for Dolutegravir / Lamivudine / Tenofovir Disproxil Fumurate tablets
  • Strides receives tentative USFDA approval for Dolutegravir tablets
  • Strides receives USFDA approval for Sevelamer Carbonate for Oral Suspension
  • Strides Pharma Science Ltd receives deferred consideration of AUD 94 million
  • Strides receives USFDA approval for Potassium Chloride Oral Solution
  • Strides receives USFDA approval for Colchicine Tablets
  • Strides receives USFDA approval for Amantadine Hydrochloride Softgel Capsules

Latest Post

  • Mphasis Reports 17.5% YoY Revenue Growth in Q1 FY27; Secures $461 Million in New Deal Wins Driven by AI Demand
  • Fractal Analytics Reports 20% Revenue Growth and 92% Surge in Net Income for Q1 FY27
  • Route Mobile Ltd Financial Results Reveal Strong Operational Top-Line Expansion for Q1 FY27 as Revenue Reaches ₹1,151.51 Crore
  • CyberTech Systems and Software Limited Reports Q1 FY27 Net Profit Up 16% YoY to ₹9.48 Crore as Operational Revenue Reaches ₹68.45 Crore
  • ACME Solar operationalizes 3.62 GWh Battery Energy Storage System projects in Rajasthan


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025